Hillsdale Investment Management Inc. Raises Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Hillsdale Investment Management Inc. lifted its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 14.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 639,100 shares of the biotechnology company’s stock after acquiring an additional 80,000 shares during the period. Hillsdale Investment Management Inc.’s holdings in BioCryst Pharmaceuticals were worth $6,084,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its holdings in BioCryst Pharmaceuticals by 34.4% in the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 44,237 shares of the biotechnology company’s stock valued at $421,000 after purchasing an additional 11,327 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of BioCryst Pharmaceuticals by 14.3% during the first quarter. Principal Financial Group Inc. now owns 430,558 shares of the biotechnology company’s stock worth $4,099,000 after buying an additional 53,990 shares in the last quarter. Candriam S.C.A. purchased a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth about $21,771,000. Hsbc Holdings PLC raised its position in shares of BioCryst Pharmaceuticals by 30.5% in the first quarter. Hsbc Holdings PLC now owns 31,499 shares of the biotechnology company’s stock valued at $303,000 after buying an additional 7,366 shares during the last quarter. Finally, Kestra Advisory Services LLC raised its position in shares of BioCryst Pharmaceuticals by 20.5% in the first quarter. Kestra Advisory Services LLC now owns 15,740 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 2,680 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

BCRX opened at $9.74 on Wednesday. The company’s 50 day simple moving average is $9.17 and its 200 day simple moving average is $8.48. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.00 and a 1 year high of $11.22. The stock has a market capitalization of $2.48 billion, a PE ratio of -5.47 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing the consensus estimate of $0.06 by ($3.04). The company had revenue of $156.41 million for the quarter, compared to analyst estimates of $151.12 million. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The business’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period last year, the company posted $0.20 EPS. As a group, sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

BCRX has been the topic of a number of analyst reports. Wall Street Zen lowered shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Cantor Fitzgerald boosted their price target on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Tuesday, June 30th. Weiss Ratings reissued a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Wedbush decreased their price objective on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Finally, Citizens Jmp lifted their price objective on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research report on Thursday, May 7th. Eight investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $20.80.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.